论文部分内容阅读
黄芪甲苷(AstragalosideIV,ASI)是黄芪中的有效成分之一,具有抗炎,改善心肌,脑缺血,促淋巴细胞繁殖,促抗体生成等作用。但由于其在黄芪中含量低,以及缺乏必要的化学合成中间体,限制了其临床药用,通过基因工程方法提高其表达量将有助于其应用。本文应用了差减杂交方法(SSH)结合斑点杂交,从黄芪甲苷合成差异株系中分离鉴定了19个黄芪甲苷合成差异基因片断,其中7个具有同源序列,同源性约80%以上,而另外12个未发现同源序列,推测可能是新基因片断或者是全长cDNA的3’末端序列。
Astragaloside IV (ASI) is one of the active ingredients in Radix Astragali. It has the effects of anti-inflammation, improving myocardial ischemia, promoting lymphocyte proliferation and promoting antibody production. However, due to its low content in Radix Astragali and the lack of the necessary chemical synthesis intermediates, which limits its clinical use, genetic engineering methods to improve its expression will help its application. In this study, we used subtractive hybridization (SSH) combined with dot blot to identify 19 differential fragments of astragaloside isolated from astragaloside synthase lines, of which 7 have homologous sequences with homology of about 80% , And the other 12 did not find homologous sequences, suggesting that it might be a new gene fragment or the 3 ’end sequence of full-length cDNA.